Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sumatriptan · 1 trial · 1 indication
Mean arterial pressure (MAP) is the average arterial pressure during a single cardiac cycle. MAP was calculated as diastolic blood pressure (DBP) + 0.33 \* (systolic blood pressure \[SBP\]-DBP). Individual time-weighted average in MAP were calculated as area under the measurement-time curve from predose through 2.5 hours of MAP divided by the time period over which the measurements were made (ie, AUCmap0-2.5 hr /2.5 hours). Data were analyzed using a linear mixed effects regression model with fixed effects for treatment and period and random effect for subject; Sumatriptan Alone data include participants from both Groups A (Parts 1 and 2) and B (Part 1 only).
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received another placebo IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2). |
| Erenumab | EXPERIMENTAL | Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received 140 mg erenumab IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2). |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered by intravenous infusion |
| Sumatriptan | DRUG | Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5 |
| Erenumab | DRUG | Administered by intravenous infusion |
Inclusion Criteria: * Healthy male and female subjects ≥ 18 to ≤ 55 years old * Good general health * Laboratory results within range * Other Inclusion Criteria May Apply Exclusion Criteria: * Female subjects pregnant or breastfeeding * An unstable medical condition * History of cancer * Active l...
Sumatriptan is a small molecule being studied in healthy subjects. It is being evaluated in a Phase 1 clinical trial to assess its effect on blood pressure when given concomitantly with subcutaneous sumatriptan. The drug is being developed by Amgen Inc. (NASDAQ: AMGN).
Sumatriptan is being developed by Amgen Inc., which is listed on the NASDAQ under the ticker symbol AMGN. The company is conducting a Phase 1 clinical trial involving the drug.
Sumatriptan is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial is completed and involved 34 healthy subjects.
Sumatriptan is associated with one completed Phase 1 clinical trial, NCT02741310, titled 'Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan.' The trial was conducted in Belgium with 34 healthy volunteers.
No, Sumatriptan is not the same as Erenumab. The clinical trial NCT02741310 evaluates the effect of Erenumab on blood pressure when given concomitantly with subcutaneous Sumatriptan, indicating they are separate drugs being studied together.